Cytokinetics
CYTK
347 hedge funds and large institutions have $9.55B invested in Cytokinetics in 2023 Q4 according to their latest regulatory filings, with 122 funds opening new positions, 74 increasing their positions, 109 reducing their positions, and 23 closing their positions.
430% more first-time investments, than exits
New positions opened: 122 | Existing positions closed: 23
197% more capital invested
Capital invested by funds: $3.22B → $9.55B (+$6.33B)
100% more funds holding in top 10
Funds holding in top 10: 10 → 20 (+10)
78% more call options, than puts
Call options by funds: $1.4B | Put options by funds: $787M
39% more funds holding
Funds holding: 250 → 347 (+97)
2.8% more ownership
Funds ownership: 113.83% → 116.63% (+2.8%)
32% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 109
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$80.8M |
| 2 |
Morgan Stanley
New York
|
+$48.9M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$38.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.8M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$36.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$54.2M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$45.6M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$44.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$34.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$32.9M |
CYTK Hedge Fund Activity: Q4 2023 in Review
347 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2023, worth a combined $9.55B — up 197% from $3.22B a quarter earlier.
Buyers outnumbered sellers: 122 funds opened new CYTK positions and 23 closed out — a net gain of 99 holders — while 74 added to existing stakes and 109 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $80.8M. The largest seller was Wellington Management Group, cutting an estimated $54.2M.
- 347 institutional investors held Cytokinetics (CYTK) as of Q4 2023, up from 250 in Q3 2023.
- Funds reported $9.55B of Cytokinetics stock for Q4 2023, up 197% quarter-over-quarter.
- 122 funds opened new Cytokinetics positions in Q4 2023 and 23 closed out, a net change of +99 holders.
- The largest Cytokinetics buyer in Q4 2023 was T. Rowe Price Associates, an estimated $80.8M added.
- The largest Cytokinetics seller in Q4 2023 was Wellington Management Group, an estimated $54.2M sold.
Based on aggregated 13F filings for Q4 2023.